Real-world multiomic characterization of small cell lung cancer subtypes to reveal differential expression of clinically relevant biomarkers.
Sonam Puri(University of Utah), Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Kathleen Kerrigan(University of Utah), Wallace Akerley(University of Utah), Hirva Mamdani(Wayne State University), Andrew Elliott(Caris Life Sciences (United States)), W. Michael Korn(Itasca Community College), Stephen V. Liu(Georgetown University), Trudy G. Oliver(Duke University), Shiven B. Patel(Huntsman Cancer Institute), Florian Kocher(Innsbruck Medical University), Dipesh Uprety(The Barbara Ann Karmanos Cancer Institute), Balázs Halmos(Montefiore Medical Center), Andreas Seeber(Innsbruck Medical University), Abdul Rafeh Naqash(Oklahoma City University), Amit Kulkarni(University of Minnesota), Gilberto Lopes(University of Miami), Hossein Borghaei(Fox Chase Cancer Center)
Cited by 12
Related Papers
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k